Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 2808 entries
Sorted by: Best Match Show Resources per page
[Dysthymia in the Clinical Context].

Revista colombiana de psiquiatria

Jiménez-Maldonado ME, Gallardo-Moreno GB, Villaseñor-Cabrera T, González-Garrido AA.
PMID: 26572816
Rev Colomb Psiquiatr. 2013 Jun;42(2):212-8. doi: 10.1016/S0034-7450(13)70008-8. Epub 2013 Aug 03.

Dysthymia is defined as a chronic mood disorder that persists for at least two years in adults, and one year in adolescents and children. According to DSM IV-TR, Dysthymia is classified into two subtypes: early-onset, when it begins before...

Cite
Jiménez-Maldonado ME, Gallardo-Moreno GB, Villaseñor-Cabrera T, et al. La distimia en el contexto clínico. [Dysthymia in the Clinical Context]. Rev Colomb Psiquiatr. 2013;42(2):212-8doi: 10.1016/S0034-7450(13)70008-8.
Jiménez-Maldonado, M. E., Gallardo-Moreno, G. B., Villaseñor-Cabrera, T., & González-Garrido, A. A. (2013). La distimia en el contexto clínico. [Dysthymia in the Clinical Context]. Revista colombiana de psiquiatria, 42(2), 212-8. https://doi.org/10.1016/S0034-7450(13)70008-8
Jiménez-Maldonado, Miriam E, et al. "La distimia en el contexto clínico." [Dysthymia in the Clinical Context]. Revista colombiana de psiquiatria vol. 42,2 (2013): 212-8. doi: https://doi.org/10.1016/S0034-7450(13)70008-8
Jiménez-Maldonado ME, Gallardo-Moreno GB, Villaseñor-Cabrera T, González-Garrido AA. La distimia en el contexto clínico. [Dysthymia in the Clinical Context]. Rev Colomb Psiquiatr. 2013 Jun;42(2):212-8. doi: 10.1016/S0034-7450(13)70008-8. Epub 2013 Aug 03. Spanish. PMID: 26572816.
Copy Download .nbib Format: NLM
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Therapeutic advances in chronic disease

Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent AC, Machado-Vieira R, Zarate CA.
PMID: 25954495
Ther Adv Chronic Dis. 2015 May;6(3):97-114. doi: 10.1177/2040622315579059.

Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All...

Cite
Iadarola ND, Niciu MJ, Richards EM, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6(3):97-114doi: 10.1177/2040622315579059.
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015). Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Therapeutic advances in chronic disease, 6(3), 97-114. https://doi.org/10.1177/2040622315579059
Iadarola, Nicolas D, et al. "Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review." Therapeutic advances in chronic disease vol. 6,3 (2015): 97-114. doi: https://doi.org/10.1177/2040622315579059
Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent AC, Machado-Vieira R, Zarate CA. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015 May;6(3):97-114. doi: 10.1177/2040622315579059. PMID: 25954495; PMCID: PMC4416968.
Copy Download .nbib Format: NLM
Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.

The Annals of pharmacotherapy

Palmer EC, Binns LN, Carey H.
PMID: 24811398
Ann Pharmacother. 2014 Aug;48(8):1030-1039. doi: 10.1177/1060028014535074. Epub 2014 May 08.

OBJECTIVE: To provide a clinical overview of the antidepressant levomilnacipran.DATA SOURCES: Articles were identified by searching the MEDLINE, PubMed, Cochrane Library, and Clinicaltrials.gov databases through March 2014 using the keyword levomilnacipran. The manufacturer provided additional information from unpublished phase...

Cite
Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother. 2014;48(8):1030-1039doi: 10.1177/1060028014535074.
Palmer, E. C., Binns, L. N., & Carey, H. (2014). Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. The Annals of pharmacotherapy, 48(8), 1030-1039. https://doi.org/10.1177/1060028014535074
Palmer, Emma C, et al. "Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder." The Annals of pharmacotherapy vol. 48,8 (2014): 1030-1039. doi: https://doi.org/10.1177/1060028014535074
Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother. 2014 Aug;48(8):1030-1039. doi: 10.1177/1060028014535074. Epub 2014 May 08. PMID: 24811398.
Copy Download .nbib Format: NLM
The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Hou YC, Lai CH.
PMID: 26598593
Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):319-20. doi: 10.9758/cpn.2015.13.3.319.

The impacts from the bupropion on the brain structures have seldom been mentioned in the literature. The bupropion is a kind of antidepressant with dual action in the norepinephrine and dopamine receptors. Here we have a case to share...

Cite
Hou YC, Lai CH. The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment. Clin Psychopharmacol Neurosci. 2015;13(3):319-20doi: 10.9758/cpn.2015.13.3.319.
Hou, Y. C., & Lai, C. H. (2015). The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 13(3), 319-20. https://doi.org/10.9758/cpn.2015.13.3.319
Hou, Yi-Cheng, and Lai, Chien-Han. "The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 13,3 (2015): 319-20. doi: https://doi.org/10.9758/cpn.2015.13.3.319
Hou YC, Lai CH. The Accompanying Changes in Brain Structure of a Remitted Depression Patient with the Bupropion Treatment. Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):319-20. doi: 10.9758/cpn.2015.13.3.319. PMID: 26598593; PMCID: PMC4662168.
Copy Download .nbib Format: NLM
Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Ram D, Patil S, Gowdappa B, Rajalakshmi I.
PMID: 26598594
Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):321-3. doi: 10.9758/cpn.2015.13.3.321.

Atomoxetine, a selective norepinephrine inhibitor, is effective in comorbid anxiety and attention deficit hyperactivity disorder, however its role in panic disorder is unknown. We are presenting a case of panic disorder, who initially partially responded to clonazepam. When clonazepam...

Cite
Ram D, Patil S, Gowdappa B, et al. Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report. Clin Psychopharmacol Neurosci. 2015;13(3):321-3doi: 10.9758/cpn.2015.13.3.321.
Ram, D., Patil, S., Gowdappa, B., & Rajalakshmi, I. (2015). Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 13(3), 321-3. https://doi.org/10.9758/cpn.2015.13.3.321
Ram, Dushad, et al. "Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 13,3 (2015): 321-3. doi: https://doi.org/10.9758/cpn.2015.13.3.321
Ram D, Patil S, Gowdappa B, Rajalakshmi I. Atomoxetine Augmentation in a Case of Treatment Resistant Panic Disorder with Multiple Augments Failure: A Case Report. Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):321-3. doi: 10.9758/cpn.2015.13.3.321. PMID: 26598594; PMCID: PMC4662177.
Copy Download .nbib Format: NLM
Degeneration in Arousal Neurons in Chronic Sleep Disruption Modeling Sleep Apnea.

Frontiers in neurology

Zhu Y, Fenik P, Zhan G, Xin R, Veasey SC.
PMID: 26074865
Front Neurol. 2015 May 26;6:109. doi: 10.3389/fneur.2015.00109. eCollection 2015.

Chronic sleep disruption (CSD) is a cardinal feature of sleep apnea that predicts impaired wakefulness. Despite effective treatment of apneas and sleep disruption, patients with sleep apnea may have persistent somnolence. Lasting wake disturbances in treated sleep apnea raise...

Cite
Zhu Y, Fenik P, Zhan G, et al. Degeneration in Arousal Neurons in Chronic Sleep Disruption Modeling Sleep Apnea. Front Neurol. 2015;6:109doi: 10.3389/fneur.2015.00109.
Zhu, Y., Fenik, P., Zhan, G., Xin, R., & Veasey, S. C. (2015). Degeneration in Arousal Neurons in Chronic Sleep Disruption Modeling Sleep Apnea. Frontiers in neurology, 6109. https://doi.org/10.3389/fneur.2015.00109
Zhu, Yan, et al. "Degeneration in Arousal Neurons in Chronic Sleep Disruption Modeling Sleep Apnea." Frontiers in neurology vol. 6 (2015): 109. doi: https://doi.org/10.3389/fneur.2015.00109
Zhu Y, Fenik P, Zhan G, Xin R, Veasey SC. Degeneration in Arousal Neurons in Chronic Sleep Disruption Modeling Sleep Apnea. Front Neurol. 2015 May 26;6:109. doi: 10.3389/fneur.2015.00109. eCollection 2015. PMID: 26074865; PMCID: PMC4443725.
Copy Download .nbib Format: NLM
Functional specificity of the locus coeruleus-norepinephrine system in the attentional networks.

Frontiers in behavioral neuroscience

Ambrosini E, Vastano R, Montefinese M, Ciavarro M.
PMID: 24376406
Front Behav Neurosci. 2013 Dec 12;7:201. doi: 10.3389/fnbeh.2013.00201. eCollection 2013.

No abstract available.

Cite
Ambrosini E, Vastano R, Montefinese M, et al. Functional specificity of the locus coeruleus-norepinephrine system in the attentional networks. Front Behav Neurosci. 2013;7:201doi: 10.3389/fnbeh.2013.00201.
Ambrosini, E., Vastano, R., Montefinese, M., & Ciavarro, M. (2013). Functional specificity of the locus coeruleus-norepinephrine system in the attentional networks. Frontiers in behavioral neuroscience, 7201. https://doi.org/10.3389/fnbeh.2013.00201
Ambrosini, Ettore, et al. "Functional specificity of the locus coeruleus-norepinephrine system in the attentional networks." Frontiers in behavioral neuroscience vol. 7 (2013): 201. doi: https://doi.org/10.3389/fnbeh.2013.00201
Ambrosini E, Vastano R, Montefinese M, Ciavarro M. Functional specificity of the locus coeruleus-norepinephrine system in the attentional networks. Front Behav Neurosci. 2013 Dec 12;7:201. doi: 10.3389/fnbeh.2013.00201. eCollection 2013. PMID: 24376406; PMCID: PMC3859899.
Copy Download .nbib Format: NLM
Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.

ACS medicinal chemistry letters

Liu S, Zha C, Nacro K, Hu M, Cui W, Yang YL, Bhatt U, Sambandam A, Isherwood M, Yet L, Herr MT, Ebeltoft S, Hassler C, Fleming L, Pechulis AD, Payen-Fornicola A, Holman N, Milanowski D, Cotterill I, Mozhaev V, Khmelnitsky Y, Guzzo PR, Sargent BJ, Molino BF, Olson R, King D, Lelas S, Li YW, Johnson K, Molski T, Orie A, Ng A, Haskell R, Clarke W, Bertekap R, O'Connell J, Lodge N, Sinz M, Adams S, Zaczek R, Macor JE.
PMID: 25050161
ACS Med Chem Lett. 2014 May 13;5(7):760-5. doi: 10.1021/ml500053b. eCollection 2014 Jul 10.

A series of 4-bicyclic heteroaryl 1,2,3,4-tetrahydroisoquinoline inhibitors of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) was discovered. The synthesis and structure-activity relationship (SAR) of these triple reuptake inhibitors (TRIs) will be discussed. Compound 10i (AMR-2),...

Cite
Liu S, Zha C, Nacro K, et al. Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors. ACS Med Chem Lett. 2014;5(7):760-5doi: 10.1021/ml500053b.
Liu, S., Zha, C., Nacro, K., Hu, M., Cui, W., Yang, Y. L., Bhatt, U., Sambandam, A., Isherwood, M., Yet, L., Herr, M. T., Ebeltoft, S., Hassler, C., Fleming, L., Pechulis, A. D., Payen-Fornicola, A., Holman, N., Milanowski, D., Cotterill, I., Mozhaev, V., Khmelnitsky, Y., Guzzo, P. R., Sargent, B. J., Molino, B. F., Olson, R., King, D., Lelas, S., Li, Y. W., Johnson, K., Molski, T., Orie, A., Ng, A., Haskell, R., Clarke, W., Bertekap, R., O'Connell, J., Lodge, N., Sinz, M., Adams, S., Zaczek, R., & Macor, J. E. (2014). Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors. ACS medicinal chemistry letters, 5(7), 760-5. https://doi.org/10.1021/ml500053b
Liu, Shuang, et al. "Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors." ACS medicinal chemistry letters vol. 5,7 (2014): 760-5. doi: https://doi.org/10.1021/ml500053b
Liu S, Zha C, Nacro K, Hu M, Cui W, Yang YL, Bhatt U, Sambandam A, Isherwood M, Yet L, Herr MT, Ebeltoft S, Hassler C, Fleming L, Pechulis AD, Payen-Fornicola A, Holman N, Milanowski D, Cotterill I, Mozhaev V, Khmelnitsky Y, Guzzo PR, Sargent BJ, Molino BF, Olson R, King D, Lelas S, Li YW, Johnson K, Molski T, Orie A, Ng A, Haskell R, Clarke W, Bertekap R, O'Connell J, Lodge N, Sinz M, Adams S, Zaczek R, Macor JE. Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors. ACS Med Chem Lett. 2014 May 13;5(7):760-5. doi: 10.1021/ml500053b. eCollection 2014 Jul 10. PMID: 25050161; PMCID: PMC4094255.
Copy Download .nbib Format: NLM
Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression.

Neural regeneration research

Zhang G, Zhang Y, Yang J, Hu M, Zhang Y, Liang X.
PMID: 25722703
Neural Regen Res. 2012 May 15;7(14):1113-8. doi: 10.3969/j.issn.1673-5374.2012.14.011.

The study examined plasma metabolite changes of monoamine neurotransmitters in patients with treatment-resistant depression (TRD) and non-TRD before and after therapy. All 30 TRD and 30 non-TRD patients met the diagnostic criteria for a depressive episode in accordance with...

Cite
Zhang G, Zhang Y, Yang J, et al. Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression. Neural Regen Res. 2012;7(14):1113-8doi: 10.3969/j.issn.1673-5374.2012.14.011.
Zhang, G., Zhang, Y., Yang, J., Hu, M., Zhang, Y., & Liang, X. (2012). Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression. Neural regeneration research, 7(14), 1113-8. https://doi.org/10.3969/j.issn.1673-5374.2012.14.011
Zhang, Guiqing, et al. "Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression." Neural regeneration research vol. 7,14 (2012): 1113-8. doi: https://doi.org/10.3969/j.issn.1673-5374.2012.14.011
Zhang G, Zhang Y, Yang J, Hu M, Zhang Y, Liang X. Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression. Neural Regen Res. 2012 May 15;7(14):1113-8. doi: 10.3969/j.issn.1673-5374.2012.14.011. PMID: 25722703; PMCID: PMC4340026.
Copy Download .nbib Format: NLM
Revisiting Antagonist Effects in Hypoglossal Nucleus: Brainstem Circuit for the State-Dependent Control of Hypoglossal Motoneurons: A Hypothesis.

Frontiers in neurology

Fenik VB.
PMID: 26648908
Front Neurol. 2015 Dec 01;6:254. doi: 10.3389/fneur.2015.00254. eCollection 2015.

We reassessed and provided new insights into the findings that were obtained in our previous experiments that employed the injections of combined adrenergic, serotonergic, GABAergic, and glycinergic antagonists into the hypoglossal nucleus in order to pharmacologically abolish the depression...

Cite
Fenik VB. Revisiting Antagonist Effects in Hypoglossal Nucleus: Brainstem Circuit for the State-Dependent Control of Hypoglossal Motoneurons: A Hypothesis. Front Neurol. 2015;6:254doi: 10.3389/fneur.2015.00254.
Fenik, V. B. (2015). Revisiting Antagonist Effects in Hypoglossal Nucleus: Brainstem Circuit for the State-Dependent Control of Hypoglossal Motoneurons: A Hypothesis. Frontiers in neurology, 6254. https://doi.org/10.3389/fneur.2015.00254
Fenik, Victor B. "Revisiting Antagonist Effects in Hypoglossal Nucleus: Brainstem Circuit for the State-Dependent Control of Hypoglossal Motoneurons: A Hypothesis." Frontiers in neurology vol. 6 (2015): 254. doi: https://doi.org/10.3389/fneur.2015.00254
Fenik VB. Revisiting Antagonist Effects in Hypoglossal Nucleus: Brainstem Circuit for the State-Dependent Control of Hypoglossal Motoneurons: A Hypothesis. Front Neurol. 2015 Dec 01;6:254. doi: 10.3389/fneur.2015.00254. eCollection 2015. PMID: 26648908; PMCID: PMC4664632.
Copy Download .nbib Format: NLM
Pathological Gambling: Neuropsychopharmacology and Treatment.

Current psychopharmacology

Bullock SA, Potenza MN.
PMID: 24349964
Curr Psychopharmacol. 2012 Feb 01;1(1). doi: 10.2174/2211556011201010067.

Pathological gambling (PG) affects about 0.2-2% of adults and the impact extends to family members, employers and society as a whole. Recent research has identified similarities in the pathophysiologies of PG and substance use disorders (SUDs). As such, findings...

Cite
Bullock SA, Potenza MN. Pathological Gambling: Neuropsychopharmacology and Treatment. Curr Psychopharmacol. 2012;1(1)doi: 10.2174/2211556011201010067.
Bullock, S. A., & Potenza, M. N. (2012). Pathological Gambling: Neuropsychopharmacology and Treatment. Current psychopharmacology, 1(1), . https://doi.org/10.2174/2211556011201010067
Bullock, Scott A, and Potenza, Marc N. "Pathological Gambling: Neuropsychopharmacology and Treatment." Current psychopharmacology vol. 1,1 (2012). doi: https://doi.org/10.2174/2211556011201010067
Bullock SA, Potenza MN. Pathological Gambling: Neuropsychopharmacology and Treatment. Curr Psychopharmacol. 2012 Feb 01;1(1). doi: 10.2174/2211556011201010067. PMID: 24349964; PMCID: PMC3860173.
Copy Download .nbib Format: NLM
Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

Citó MC, Silva MI, Santos LK, Fernandes ML, Melo FH, Aguiar JA, Lopes IS, Sousa PB, Vasconcelos SM, Macêdo DS, Sousa FC.
PMID: 25493384
Braz J Med Biol Res. 2015 Jan;48(1):57-64. doi: 10.1590/1414-431x20144215. Epub 2014 Nov 07.

Hoodia gordonii is a plant species used traditionally in southern Africa to suppress appetite. Recently, it has been associated with a significant increase in blood pressure and pulse rate in women, suggesting sympathomimetic activity. The present study investigated the...

Cite
Citó MC, Silva MI, Santos LK, et al. Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system. Braz J Med Biol Res. 2014;48(1):57-64doi: 10.1590/1414-431x20144215.
Citó, M. C., Silva, M. I., Santos, L. K., Fernandes, M. L., Melo, F. H., Aguiar, J. A., Lopes, I. S., Sousa, P. B., Vasconcelos, S. M., Macêdo, D. S., & Sousa, F. C. (2015). Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 48(1), 57-64. https://doi.org/10.1590/1414-431x20144215
Citó, M C O, et al. "Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system." Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas vol. 48,1 (2015): 57-64. doi: https://doi.org/10.1590/1414-431x20144215
Citó MC, Silva MI, Santos LK, Fernandes ML, Melo FH, Aguiar JA, Lopes IS, Sousa PB, Vasconcelos SM, Macêdo DS, Sousa FC. Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system. Braz J Med Biol Res. 2015 Jan;48(1):57-64. doi: 10.1590/1414-431x20144215. Epub 2014 Nov 07. PMID: 25493384; PMCID: PMC4288494.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 2808 entries